Stem Cell Transplant for Chronic Myeloid Leukemia in the Imatinib Era

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 354-361

  Radich, Jerald ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE FREE SURVIVAL; DONOR SELECTION; HLA TYPING; HUMAN; LEUKEMIA RELAPSE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77957088676     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.06.008     Document Type: Article

References (49)

1. Thomas E.D., Clift R.A., Fefer A., et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986, 104:155-163.
2. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102:31-35.
3. Saussele S., Lauseker M., Gratwohl A., et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010, 115:1880-1885.
4. Devergie A., Reiffers J., Vernant J.P., et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990, 5:379-386.
5. Martin P.J., Clift R.A., Fisher L.D., et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988, 72:1978-1984.
6. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994, 84:4368-4373.
7. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
8. Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987, 70. 1382-18.
9. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994, 84:2036-2043.
10. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
11. Clift R.A., Appelbaum F.R., Thomas E.D. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993, 82:1954-1956.
12. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998, 338:962-968.
13. Enright H., Daniels K., Arthur D.C., et al. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 1996, 17:537-542.
14. Goldman J.M., Szydlo R., Horowitz M.M., et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993, 82:2235-2238.
15. Davies S.M., DeFor T.E., McGlave P.B., et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001, 110:339-346.
16. Fefer A., Cheever M.A., Thomas E.D., et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979, 300:333-337.
17. Fefer A., Cheever M.A., Greenberg P.D., et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 1982, 306:63-68.
18. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
19. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002, 100:1525-1531.
20. Oehler V.G., Radich J.P., Storer B., et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005, 11:85-92.
21. Hehlmann R., Hochhaus A., Kolb H.J., et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999, 94:3668-3677.
22. Shimoni A., Kroger N., Zander A.R., et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003, 17:290-297.
23. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006, 91:452-459.
24. Zaucha J.M., Prejzner W., Giebel S., et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005, 36:417-424.
25. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007, 109:1782-1789.
26. Lee S.J., Kkreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008, 112:3500-3507.
27. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
28. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998, 352:1087-1092.
29. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
30. Kerbauy F.R., Storb R., Hegenbart U., et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005, 19:990-997.
31. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003, 101:441-445.
32. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005, 106:2969-2976.
33. Radich J., Gehly G., Lee A., et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, 89:2602-2609.
34. Radich J.P., Gooley T., Bryant E., et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001, 98:1701-1707.
35. Higano C.S., Chielens D., Raskind W., et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997, 90:2549-2554.
36. Kantarjian H.M., Talpaz M., O'Brien S., et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002, 8:2177-2187.
37. Olavarria E., Craddock C., Dazzi F., et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002, 99:3861-3862.
38. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
39. Tam C.S., Kantarjian H., Garcia-Manero G., et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008, 112:516-518.
40. Hehlmann R., Berger U., Pfirrmann M., et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007, 109:4686-4692.
41. Gratwohl A., Baldomero H., Aljurf M., et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010, 303:1617-1624.
42. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213.
43. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
44. Kantarjian H., Pasquini R., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
45. Hughes T., Saglio G., Branford S., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27:4204-4210.
46. Muller M.C., Cortes J.E., Kim D.W., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
47. Soverini S., Gnani A., Colarossi S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
48. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood;115:315-25.
49. Oehler V.G., Yeung K.Y., Choi Y.E., Bumgarner R.E., Raftery A.E., Radich J.P. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009, 114:3292-3298.